news
HPAPI market to value $27bn by 2025
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
List view / Grid view
Sanofi
news
ATOM partnership seeks to increase access to cancer medicines in LLMICs
A unique partnership, the Access to Oncology Medicines (ATOM) Coalition, has been established to ensure sustainable access to cancer medicines in low- and lower middle-income countries (LLMICs) in the long-term.
news
Adding Sarclisa® provides “unprecedented” multiple myeloma survival, finds trial
Combining Sarclisa® (isatuximab) with carfilzomib and dexamethasone (Kd) resulted in more than three years of progression free survival for relapsed multiple myeloma patients.
news
Sanofi and McLaren Racing partner for manufacturing excellence
Following a successful pilot in 2021, Sanofi and McLaren Racing have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines, across all technologies.
news
Sanofi begins construction of Singapore vaccine facility
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
news
Sanofi launches pharma’s first Diversity, Equity & Inclusion Board
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
news
Sanofi and Blackstone €300 million collaboration to advance multiple myeloma treatment
The investment will advance the development of a subcutaneous Sarclisa (isatuximab) formulation for multiple myeloma (MM) treatment.
news
Efanesoctocog alfa prevents bleeding episodes in haemophilia A patients
Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients, according to new Phase III data.
news
Nirsevimab first potential immunisation to protect against RSV in infants
Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.
news
Pistoia Alliance launches Women in STEM leadership pilot
A new collaborative initiative involving 15 large pharma companies will support diversity in executive roles and cross-company leadership skills development.
article
2021 bio/pharma financial round-up
European Pharmaceutical Review investigates the financial results of some of the top 10 pharma and biopharma companies worldwide.
news
Nexviazyme® improves respiration and mobility long-term in Pompe disease patients
Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility.
news
Sanofi to acquire Origimm Biotechnology to develop acne vaccine
Sanofi has entered into an agreement to acquire Origimm Biotechnology to add a potential first-in-class vaccine for acne to their pipeline.
news
Sanofi invests $180 million in Owkin’s AI to advance oncology pipeline
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
news
Energize initiative to boost renewable energy access for pharma suppliers
The Energize programme will allow 10 big pharma companies to engage with renewable energy suppliers and address their greenhouse gas emissions.
